[go: up one dir, main page]

WO2003032963A3 - Method of reducing type 2 diabetes in high risk patients - Google Patents

Method of reducing type 2 diabetes in high risk patients Download PDF

Info

Publication number
WO2003032963A3
WO2003032963A3 PCT/EP2002/011636 EP0211636W WO03032963A3 WO 2003032963 A3 WO2003032963 A3 WO 2003032963A3 EP 0211636 W EP0211636 W EP 0211636W WO 03032963 A3 WO03032963 A3 WO 03032963A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
high risk
prevention
risk patients
reducing type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/011636
Other languages
French (fr)
Other versions
WO2003032963A2 (en
Inventor
Salim Yusuf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Priority to CA002463682A priority Critical patent/CA2463682A1/en
Priority to EP02790295A priority patent/EP1438043A2/en
Priority to IL16138802A priority patent/IL161388A0/en
Priority to JP2003535767A priority patent/JP2005531492A/en
Priority to US10/492,919 priority patent/US20050065203A1/en
Priority to MXPA04003022A priority patent/MXPA04003022A/en
Publication of WO2003032963A2 publication Critical patent/WO2003032963A2/en
Publication of WO2003032963A3 publication Critical patent/WO2003032963A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to the use of an angiotensin converting enzyme (ACE) inhibitor such as ramipril or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention or reduction of the onset of diabetes in patients who are at risk for developing diabetes; for the prevention, slowing or reversing the decline of beta-cell function; for increasing islet blood flow; for increasing pancreatic beta-cell perfusion; and for lowering aldosterone secretion and renal potassium wasting.
PCT/EP2002/011636 2001-10-17 2002-10-17 Method of reducing type 2 diabetes in high risk patients Ceased WO2003032963A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002463682A CA2463682A1 (en) 2001-10-17 2002-10-17 Method of reducing type 2 diabetes in high risk patients
EP02790295A EP1438043A2 (en) 2001-10-17 2002-10-17 Method of reducing type 2 diabetes in high risk patients
IL16138802A IL161388A0 (en) 2001-10-17 2002-10-17 Method of reducing type 2 diabetes in high risk patients
JP2003535767A JP2005531492A (en) 2001-10-17 2002-10-17 Method for reducing type II diabetes in high-risk patients
US10/492,919 US20050065203A1 (en) 2001-10-17 2002-10-17 Method of reducing type 2 diabetes in high risk patients
MXPA04003022A MXPA04003022A (en) 2001-10-17 2002-10-17 Method of reducing type 2 diabetes in high risk patients.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34449501P 2001-10-17 2001-10-17
US60/344495 2001-10-17

Publications (2)

Publication Number Publication Date
WO2003032963A2 WO2003032963A2 (en) 2003-04-24
WO2003032963A3 true WO2003032963A3 (en) 2003-12-24

Family

ID=23350759

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2002/033213 Ceased WO2003032965A2 (en) 2001-10-17 2002-10-17 Use of ace inhibitors for reducing type 2 diabetes in high risk patients
PCT/EP2002/011636 Ceased WO2003032963A2 (en) 2001-10-17 2002-10-17 Method of reducing type 2 diabetes in high risk patients

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033213 Ceased WO2003032965A2 (en) 2001-10-17 2002-10-17 Use of ace inhibitors for reducing type 2 diabetes in high risk patients

Country Status (7)

Country Link
EP (1) EP1438043A2 (en)
JP (1) JP2005531492A (en)
AU (1) AU2002335843A1 (en)
CA (1) CA2463682A1 (en)
IL (1) IL161388A0 (en)
MX (1) MXPA04003022A (en)
WO (2) WO2003032965A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2458288A1 (en) * 2003-03-11 2004-09-11 Institut De Cardiologie De Montreal / Montreal Heart Institute Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure
WO2005020984A2 (en) * 2003-08-29 2005-03-10 Aaipharma Inc. Method of reducing the risk of oxidative stress
BRPI0716411A2 (en) * 2006-08-28 2013-09-24 Sanofi Aventis Deutschland Methods for Lowering Glucose Levels
CA3147180C (en) 2013-03-14 2024-04-23 Amgen Inc. Controlled release formulations of omecamtiv mecarbil comprising a ph modifying agent
PT3015106T (en) * 2013-06-26 2021-09-06 Univ Korea Res & Bus Found Composition for preventing or treating renal diseases, containing dpp-iv inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331014A2 (en) * 1988-03-02 1989-09-06 THERA - Patent Verwaltungs-GmbH Use of ACE inhibitors in diabetes prophylaxis
DE4308504A1 (en) * 1993-03-18 1994-09-22 Knoll Ag New use of a combination of verapamil and trandolapril
WO2001015674A2 (en) * 1999-08-30 2001-03-08 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2001015673A2 (en) * 1999-08-27 2001-03-08 Aventis Pharma Deutschland Gmbh Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331014A2 (en) * 1988-03-02 1989-09-06 THERA - Patent Verwaltungs-GmbH Use of ACE inhibitors in diabetes prophylaxis
DE4308504A1 (en) * 1993-03-18 1994-09-22 Knoll Ag New use of a combination of verapamil and trandolapril
WO2001015673A2 (en) * 1999-08-27 2001-03-08 Aventis Pharma Deutschland Gmbh Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
WO2001015674A2 (en) * 1999-08-30 2001-03-08 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.", LANCET. ENGLAND 22 JAN 2000, vol. 355, no. 9200, 22 January 2000 (2000-01-22), pages 253 - 259, XP002232380, ISSN: 0140-6736 *
BAKRIS GEORGE L ET AL: "ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure", KIDNEY INTERNATIONAL, NEW YORK, NY, US, vol. 58, no. 5, November 2000 (2000-11-01), pages 2084 - 2092, XP001164193, ISSN: 0085-2538 *
CARLSSON P-O ET AL: "Angiotensin II and the endocrine pancreas: Effects on islet blood flow and insulin secretion in rats", DIABETOLOGIA 1998 GERMANY, vol. 41, no. 2, 1998, pages 127 - 133, XP001148412, ISSN: 0012-186X *
GALLETTI F ET AL: "CONTROLLED STUDY OF THE EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITION VERSUS CALCIUM-ENTRY BLOCKADE ON INSULIN SENSITIVITY IN OVERWEIGT HYPERTENSIVE PATIENTS: TRANDOLAPRIL ITALIAN STUDY (TRIS)", JOURNAL OF HYPERTENSION, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 17, no. 3, March 1999 (1999-03-01), pages 439 - 445, XP008014000, ISSN: 0263-6352 *
JANKA H U ET AL: "Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus.", ARZNEIMITTEL-FORSCHUNG. GERMANY, WEST APR 1990, vol. 40, no. 4, April 1990 (1990-04-01), pages 432 - 435, XP001109698, ISSN: 0004-4172 *
KEILANI T ET AL: "Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium", JOURNAL OF CLINICAL PHARMACOLOGY, LIPPINCOTT CO, HAGERSTOWN, MD, US, vol. 35, no. 1, January 1995 (1995-01-01), pages 87 - 97, XP008021110, ISSN: 0091-2700 *
KRÜTZFELDT J ET AL: "Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats.", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY. GERMANY JUL 2000, vol. 362, no. 1, July 2000 (2000-07-01), pages 1 - 6, XP001148413, ISSN: 0028-1298 *
TAHMASEBI M ET AL: "THE TISSUE RENIN-ANGIOTENSIN SYSTEM IN HUMAN PANCREAS", JOURNAL OF ENDOCRINOLOGY, BRISTOL, GB, vol. 161, no. 2, 1999, pages 317 - 322, XP008014002, ISSN: 0022-0795 *
YUSUF S ET AL: "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.", THE NEW ENGLAND JOURNAL OF MEDICINE. UNITED STATES 20 JAN 2000, vol. 342, no. 3, 20 January 2000 (2000-01-20), pages 145 - 153, XP008013952, ISSN: 0028-4793 *
YUSUF S ET AL: "RAMIPRIL AND THE DEVELOPMENT OF DIABETES", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, CHICAGO,IL, US, vol. 286, no. 15, 17 October 2001 (2001-10-17), pages 1882 - 1885, XP008013945, ISSN: 0098-7484 *

Also Published As

Publication number Publication date
MXPA04003022A (en) 2004-07-05
WO2003032965A3 (en) 2003-11-27
IL161388A0 (en) 2004-09-27
WO2003032965A2 (en) 2003-04-24
EP1438043A2 (en) 2004-07-21
AU2002335843A1 (en) 2003-04-28
WO2003032963A2 (en) 2003-04-24
JP2005531492A (en) 2005-10-20
CA2463682A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
UA88265C2 (en) Use of inhibitors of the renin-angiotensin system in the prevention of diabetes
EP1212081B8 (en) Use of ace inhibitors in the prevention of congestive heart failure
CA2368186A1 (en) Use of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
WO2004080482A8 (en) Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure
WO2003032963A3 (en) Method of reducing type 2 diabetes in high risk patients
MXPA03006477A (en) Method of treatment of type i diabetes.
IS7418A (en) Citalopram to treat elevated blood pressure
WO2004071384A3 (en) New pharmaceutical compositions based on anticholinergics and tace-inhibitors
EP1611886A3 (en) Inhibitors of the renin-angiotensin system for the prevention of cardiovascular disorders
AU2002328948A1 (en) New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels
HK1061195A (en) New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels
UA6306U (en) Method for treating disorders of hepatic blood circulation in patients with arterial hypertension and heart failure
AU2002228391A1 (en) Medicinal composition for diagnosis, prevention, or therapy of multiple risk factor syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/003022

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002790295

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 161388

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2463682

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002362897

Country of ref document: AU

Ref document number: 2003535767

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002790295

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10492919

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002790295

Country of ref document: EP